Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
|Articles|September 29, 2016
Treatment Strategies for Mohs Disease
Aleksandar L. Krunic, MD, PhD, discusses tumor removal in Mohs disease during the 25th European Academy of Dermatology and Venereology Congress.
Advertisement
Aleksandar L. Krunic, MD, PhD, dermatologic surgeon and assistant professor of dermatology at University of Illinois College of Medicine, discusses which tumor types are best removed in Mohs disease, during the 25th European Academy of Dermatology and Venereology Congress,
held September 28 to October 2, in Vienna, Austria.
Advertisement
Related to this article
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5